6.
Owczarzak J, Monton O, Fuller S, Burlaka J, Kiriazova T, Morozova O
. "Will you need this health at all? Will you be alive?": using the bioecological model of mass trauma to understand HIV care experiences during the war in Ukraine. J Int AIDS Soc. 2024; 27 Suppl 3:e26307.
PMC: 11258484.
DOI: 10.1002/jia2.26307.
View
7.
Malaba T, Nakatudde I, Kintu K, Colbers A, Chen T, Reynolds H
. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Lancet HIV. 2022; 9(8):e534-e543.
DOI: 10.1016/S2352-3018(22)00173-4.
View
8.
Orkin C, Schapiro J, Perno C, Kuritzkes D, Patel P, DeMoor R
. Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure. Clin Infect Dis. 2023; 77(10):1423-1431.
PMC: 10654860.
DOI: 10.1093/cid/ciad370.
View
9.
Landovitz R, Hanscom B, Clement M, Tran H, Kallas E, Magnus M
. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a.... Lancet HIV. 2023; 10(12):e767-e778.
PMC: 11375758.
DOI: 10.1016/S2352-3018(23)00261-8.
View
10.
Vasylyev M, Skrzat-Klapaczynska A, Bernardino J, Sandulescu O, Gilles C, Libois A
. Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine. Lancet HIV. 2022; 9(6):e438-e448.
DOI: 10.1016/S2352-3018(22)00125-4.
View
11.
Hankins C, Koulla-Shiro S, Kilmarx P, Ferrari G, Schechter M, Toure Kane C
. Ending AIDS as a public health threat by 2030: Scientific Developments from the 2016 INTEREST Conference in Yaoundé, Cameroon. Antivir Ther. 2017; 22(2):179-184.
PMC: 5542813.
DOI: 10.3851/IMP3165.
View
12.
Benade M, Maskew M, Juntunen A, Flynn D, Rosen S
. Prior exposure to antiretroviral therapy among adult patients presenting for HIV treatment initiation or reinitiation in sub-Saharan Africa: a systematic review. BMJ Open. 2023; 13(11):e071283.
PMC: 10660894.
DOI: 10.1136/bmjopen-2022-071283.
View
13.
Deblonde J, Sasse A, Del Amo J, Burns F, Delpech V, Cowan S
. Restricted access to antiretroviral treatment for undocumented migrants: a bottle neck to control the HIV epidemic in the EU/EEA. BMC Public Health. 2015; 15:1228.
PMC: 4676131.
DOI: 10.1186/s12889-015-2571-y.
View
14.
Gokengin D, Oprea C, Begovac J, Horban A, Zeka A, Sedlacek D
. HIV care in Central and Eastern Europe: How close are we to the target?. Int J Infect Dis. 2018; 70:121-130.
DOI: 10.1016/j.ijid.2018.03.007.
View
15.
Pottie K, Lotfi T, Kilzar L, Howeiss P, Rizk N, Akl E
. The Effectiveness and Cost-Effectiveness of Screening for HIV in Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health. 2018; 15(8).
PMC: 6121945.
DOI: 10.3390/ijerph15081700.
View
16.
Sullivan A, Saunders J, Desai M, Cartier A, Mitchell H, Jaffer S
. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment. Lancet HIV. 2023; 10(12):e790-e806.
PMC: 7616873.
DOI: 10.1016/S2352-3018(23)00256-4.
View
17.
Kityo C, Mambule I, Musaazi J, Sokhela S, Mugerwa H, Ategeka G
. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024; 24(10):1083-1092.
DOI: 10.1016/S1473-3099(24)00289-5.
View
18.
Kuchukhidze G, Otani M, Bivol S, Noori T
. Refugees from Ukraine receiving antiretroviral therapy in destination countries and territories of the World Health Organization European Region, including EU/EEA countries, February 2022 to March 2023. Euro Surveill. 2024; 29(24).
PMC: 11177572.
DOI: 10.2807/1560-7917.ES.2024.29.24.2300567.
View
19.
Raccagni A, Galli L, Lucente M, Candela C, Lolatto R, Trentacapilli B
. High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy. AIDS Behav. 2023; 28(3):907-911.
DOI: 10.1007/s10461-023-04197-8.
View
20.
Reyes-Uruena J, Marrone G, Noori T, Kuchukhidze G, Martsynovska V, Hetman L
. HIV diagnoses among people born in Ukraine reported by EU/EEA countries in 2022: impact on regional HIV trends and implications for healthcare planning. Euro Surveill. 2023; 28(48).
PMC: 10690861.
DOI: 10.2807/1560-7917.ES.2023.28.48.2300642.
View